Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...